AIM Admission - First Day of Dealings

3 June 2014

Biofrontera AG Admission and First Day of Dealings

("Biofrontera" or "the Company")

Biofrontera AG (AIM/FSE:B8F), the European biopharmaceutical company, is pleased to announce that Admission and trading of its Ordinary Shares commences at 8.00am today on the AIM market of the London Stock Exchange ("AIM").

Admission details

· Total number of Ordinary Shares in issue at Admission is 22,196,570, giving the Company a market capitalisation of approximately €69.9m;

· finnCap is acting as Nominated Advisor and broker to the Company; and

· Biofrontera's TIDM Code is B8F and its ISIN number is DE0006046113.

Biofrontera specialises in the development of dermatological drugs, medical devices and medical cosmetics for the treatment and care of skin diseases. Fully listed in Frankfurt (B8F), the Company has also applied to the Frankfurt Stock Exchange to list its shares in the "Prime Standard" segment moving up from the regulated market segment "General Standard".

The Company developed and distributes Ameluz® a prescription drug to treat Actinic Keratosis, a superficial skin cancer. The drug is used in combination with a red light source, the so-called photodynamic therapy ("PDT"). Ameluz® in combination with PDT is the most efficacious therapy for Actinic Keratosis currently on the market. Biofrontera is in the process of extending the indication for Ameluz® to Basal Cell Carcinoma, the most frequently occurring infiltrating tumour in humans.

European and US Growth - Ameluz® received a centralized approval in the EU in December 2011 and was launched in Germany in 2012 and in less than a year Biofrontera rapidly achieved over 65% market share in prescription drugs used in PDT in Germany. The Company is now focussing on accelerating growth in European sales through regional representatives. For US approval, Biofrontera is currently working towards completing clinical trials and documentation as requested by the FDA and anticipates a regulatory submission in early 2015, which would then lead to an anticipated launch into the US market in 2016.

Treatment - In PDT Ameluz® is applied to the skin. Through a 10 to 15 minute illumination with a strong red light a chemical reaction is triggered three hours later. The tumour cells will then selectively be killed without any scar formation. Due to stimulation of collagen synthesis in the dermis (the middle layer of the skin), the PDT will also have a strong, long-lasting skin rejuvenation effect. In Northern Europe alone, 11-12% of adults have Actinic Keratosis and it is well documented that if left untreated, these skin lesions can progress into malignant forms of skin cancer.

Strategy - Biofrontera raised €15.3 million net proceeds from its existing shareholders earlier this year, to fund the indication of Ameluz® to treat Basal Cell Carcinoma; to significantly increase sales and marketing activity across Europe; and for the preparation of the US FDA approval. The AIM listing will provide a platform for the company to build on its institutional and international investor base in line with its growth potential over the coming years.

The management team is focused on further increasing revenues in 2015 by:

· Accelerating sales of Ameluz® in more European countries and extending the indication to also treat Basal Cell Carcinoma

· Achieving FDA approval in the US, thereby opening up the North American market for sales in 2016

Executive Directors

Prof. Hermann Lübbert - Chief Executive Officer

Hermann founded Biofrontera in 1997. He studied Biology in his native city of Cologne, where he completed a PhD in 1984. After eight years of academic research at the University of Cologne and the California Institute of Technology (USA), he spent ten years gaining experience in global research management at Sandoz and Novartis Pharma AG, prior to establishing Biofrontera. He was awarded his habilitation at the ETH (Eidgenössische Technische Hochschule) Zürich and holds the Chair of Animal Physiology at Ruhr-University Bochum.

Thomas Schaffer - Chief Financial Officer

Thomas was appointed CFO and joined the Company in June 2013. He started his career in various functions in Finance at Siemens Semiconductor, where he reached the position of Vice President and CFO of the Security & Chipcard ICs. After four years as Managing Director and CFO of Infineon Ventures GmbH, he continued as Vice President and CFO of the Specialty DRAM Division of Qimonda AG and became Managing Director of Qimonda Solar GmbH. He has held CFO positions at Heptagon Oy, Finland/Switzerland, and Ubidyne Inc., Delaware, USA.

Prof. Hermann Lübbert, CEO of Biofrontera commented: "We are delighted to be joining the London Stock Exchange, as the AIM listing will provide a platform for Biofrontera to build on its institutional and international investor base, who have expressed significant support of this move as they have followed the Company for the past year or so.

"We have some major milestones in the near future to help us build on Biofrontera's growth potential and ultimately to deliver shareholder value. Biofrontera looks to further increase revenues in 2015 by accelerating sales of Ameluz® in more European countries and extending the indication to also treat Basal Cell Carcinoma as well as working towards achieving FDA approval in the US, thereby opening up the North American market for sales in 2016. We are looking forward to UK investors joining Biofrontera on its exciting next steps in becoming an international pharmaceutical company."

The admission document can be found on the Company's website: www.biofrontera.com

Enquiries

Notes to Editors:

Biofrontera AG (AIM / FSE: B8F) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs and medical cosmetics for the treatment and care of skin diseases. Biofrontera's main product is Ameluz®, a prescription drug approved for use in Europe for the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by photodynamic therapy (light therapy). Biofrontera is the first small German pharmaceutical company to receive a centralized approval for a drug developed in-house. The Company is looking to further develop Ameluz for use in Basal Cell Carcinoma and is currently progressing through regulatory approvals to sell the product in other territories, in particular the largest pharmaceutical market, the USA.

In addition, the Company markets the Belixos cosmetic series with plant extracts, currently available in cream and liquid formulations which offer nurturing and regenerating effects for people suffering from pruritus, dry skin or chronic ailments such as eczema or psoriasis.

Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the CEO, and is headquartered in Leverkusen, Germany.

www.biofrontera.com